Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b study of VYN202 in in moderate-to-severe adult-onset rheumatoid arthritis.

Next Previous
Trial Profile

A phase 1b study of VYN202 in in moderate-to-severe adult-onset rheumatoid arthritis.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VYN 202 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 02 Jul 2025 Results presented in the VYNE Therapeutics media release.
  • 02 Jul 2025 According to a VYNE Therapeutics media release,The Company believes that the totality of the data from this study, together with promising results from multiple preclinical models, support the continued advancement of VYN202 into serious, immune-mediated diseases with limited effective treatment options. Based on this assessment, the Company will no longer enroll patients in the Phase 1b psoriasis study, extending the Companys expected cash runway into the fourth quarter of 2026.
  • 02 Jul 2025 According to a VYNE Therapeutics media release, company provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Companys Phase 1b clinical trial in the treatment of moderate-to-severe plaque psoriasis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top